| Symbol | FMS |
|---|---|
| Name | FRESENIUS MEDICAL CARE AG |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 61346 Germany Else-Kroner Strasse 1 |
| Telephone | +49 6172 608 2522 |
| Fax | — |
| — | |
| Website | http://www.freseniusmedicalcare.com/en/investors/i |
| Incorporation | DE |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001333141 |
| Description | Fresenius Medical Care is the worlds largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.5 million individuals worldwide. Through its network of 3,250 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 270.122 patients around the globe. Fresenius Medical Care is also the worlds leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Additional info from NASDAQ: Additional info from OTC: |
New Form 3 - Fresenius Medical Care AG <b>Filed:</b> 2026-03-18 <b>AccNo:</b> 0001104659-26-030144 <b>Size:</b> 17 KB
Read moreNew Form IRANNOTICE - Fresenius Medical Care AG <b>Filed:</b> 2026-02-24 <b>AccNo:</b> 0001104659-26-019011 <b>Size:</b> 12 KB
Read moreFresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
Read moreFresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01887262 | Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on P… | Na | Peritoneal Dialysis, Continuous Ambulatory | Completed | 2013-07-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01997385 | The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Pat… | Phase4 | Renal Insufficiency, Chronic | Completed | 2012-06-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01668628 | Quality of Life and Depression in Dialysis Patients | — | Chronic Kidney Disease Stage 5 | Completed | 2010-08-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01315314 | Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction | Phase4 | Kidney Failure, Chronic | Completed | 2005-10-01 | 2008-04-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Balance, Fresenius Medical Care, Germany | Other | Phase PHASE4 | Kidney Failure, Chronic | COMPLETED | NCT01315314 |
| KAPD-A | Other | Phase PHASE4 | Renal Insufficiency, Chronic | COMPLETED | NCT01997385 |
| KAPD-C | Other | Phase PHASE4 | Renal Insufficiency, Chronic | COMPLETED | NCT01997385 |
| Fluid management based on the clinical information alone | Other | Approved | Peritoneal Dialysis, Continuous Ambulatory | COMPLETED | NCT01887262 |
| BCM-guided fluid management | Other | Approved | Peritoneal Dialysis, Continuous Ambulatory | COMPLETED | NCT01887262 |